Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

Conference Coverage

Experimental Bioactive Cream DS101 Demonstrates Efficacy at Reducing Rosacea Symptoms

John Otrompke, BA, JD

    Treatment with the novel bioactive lipid cream DS101 was associated with decreased rosacea severity by more than half (57%; p<0.001) as measured by investigator's global assessment (IGA), according to results from a single-center, open-label trial. These data are being presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting.

“DS101’s active ingredients are anti-inflammatory, anti-oxidative and photo-protective against ultraviolet radiation,” wrote lead author Moayed Hamza, MBBcH, DS Biopharma, Dublin, Ireland, and co-authors. The experimental substance contains a combination of the omega-3 fatty acid eicosapentaenoic acid and the omega-6 fatty acid gamma-linolenic acid.

In the study, researchers evaluated the progress of 20 adults with mild-to-moderate rosacea and sensitive skin who applied DS101 cream twice-daily on their entire face for 12 weeks. Secondary endpoints were clinician erythema assessment, investigator- and subject-reported assessments of efficacy and tolerability, corneometer assessment of skin hydration, and trans-epidermal water loss.

The difference in the primary endpoint of improvement in rosacea severity, was already apparent at week 4 (37%; p=0.001). DS101 was also associated with significantly decreased erythema (-41%; p=0.007), as well as significantly increased skin water content (34%; p<0.001) both at week 12. There were also improvements in IGA of redness (-62%), dryness (-86%), evenness of tone (+43%), visual smoothness (+56%), tactile softness (+72%), clarity (+42%), radiance (+55%), and overall skin appearance (+42%).

Improvements were also recorded for all subject-reported efficacy assessments. No adverse events were reported.

Reference
Hamza M, Draelos Z, Lafferty A, et al. Effects of DS101 cream on mild-to-moderate rosacea: results from an open-label study. Poster presented at: AAD Annual Meeting. March 25-29, 2022; Boston, MA.

Advertisement

Advertisement

Advertisement